Adhering to diets that exclude gluten may lead to improvements in fatigue, quality of life, and some measures of disability in people with multiple sclerosis (MS), but it remains unclear whether these benefits stem from avoiding gluten itself or other dietary changes, a review of six studies found. Overall, the…
Discussion
I am using the start of November as an opportunity to pause, reflect, and think about what I am thankful for. As we enter a month often associated with gratitude, family, and togetherness, I find myself thinking about what thankfulness looks like when you are living with multiple sclerosis…
Discussion
Children and teenagers in Canada with relapsing-remitting multiple sclerosis (RRMS) now have a second treatment option following Health Canada’s approval of the infusion therapy Ocrevus (ocrelizumab). The regulatory decision extends the use of Ocrevus to patients 10 and older. Previously authorized in Canada only for adults, Ocrevus joins…
Discussion
A lower dose of the experimental therapy foralumab significantly reduced a marker of brain inflammation in people with nonactive secondary progressive multiple sclerosis (SPMS), according to top-line results from a Phase 2 clinical trial. The 12-week study, called INFORM-MS (NCT06292923), met both its main goals.
Discussion
The experimental oral therapy remibrutinib significantly reduced relapse rates and brain lesion activity more than the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials of people with relapsing forms of multiple sclerosis (MS). The trials, REMODEL-1 (NCT05147220) and REMODEL-2 (NCT05156281), compared remibrutinib with…
Get regular updates to your inbox.
